Risk factor
Poor trading liquidity
Profitability factor
Undervalued vs peers
About
Huons Co., Ltd. operates as a global healthcare company, providing a broad spectrum of medical solutions designed to enhance human health in South Korea and worldwide. Its extensive product line includes a variety of oral solid medications targeting numerous conditions, such as those affecting the circulatory and metabolic systems, pain and inflammation (antipyretic, analgesic, anti-inflammatory), musculoskeletal and digestive health, allergies (antihistamines), respiratory ailments, infections (antibiotics), and products for general well-being, urogenital issues, and various chemotherapeutic applications. The company also manufactures a comprehensive range of injectable pharmaceuticals. These span categories like anesthetics, pain and fever reducers, anti-inflammatory agents, muscle relaxants, antispasmodics, antihistamines, and treatments for circulatory and respiratory system disorders. Further offerings in this format include adrenocortical hormones, enzymes, minerals, solvents, calcium supplements, hemostatics, antidotes, antibiotics, metabolic aids, hyaluronic acid, wellness formulations, anticoagulants, and specialized products for tissue and cell systems. In addition to its pharmaceutical offerings, Huons provides ophthalmic solutions (eye drops), various biological products, and medical devices. Established in 1965 and headquartered in Seongnam, South Korea, the company was initially known as Kwang Myung Pharm before officially changing its name to Huons Co., Ltd. in June 2003.
Company Valuation
From both historical and forecast perspectives, the stock is underpriced compared to similar stocks. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA,